Lantheus Holdings, Inc. to Post Q1 2024 Earnings of $1.47 Per Share, Leerink Partnrs Forecasts (NASDAQ:LNTH)

Lantheus Holdings, Inc. (NASDAQ:LNTH) – Equities researchers at Leerink Partnrs decreased their Q1 2024 earnings estimates for Lantheus in a research report issued to clients and investors on Wednesday, April 17th. Leerink Partnrs analyst R. Ruiz now expects that the medical equipment provider will post earnings per share of $1.47 for the quarter, down from their previous estimate of $1.48. The consensus estimate for Lantheus’ current full-year earnings is $5.72 per share. Leerink Partnrs also issued estimates for Lantheus’ Q2 2024 earnings at $1.49 EPS, FY2024 earnings at $5.92 EPS and FY2025 earnings at $5.49 EPS.

Lantheus (NASDAQ:LNTH) last released its quarterly earnings results on Thursday, February 22nd. The medical equipment provider reported $1.59 earnings per share for the quarter, beating analysts’ consensus estimates of $1.33 by $0.26. The company had revenue of $354.00 million for the quarter, compared to analysts’ expectations of $350.44 million. Lantheus had a return on equity of 63.16% and a net margin of 25.20%.

A number of other equities research analysts have also recently weighed in on LNTH. StockNews.com raised Lantheus from a “hold” rating to a “buy” rating in a report on Saturday, January 13th. Truist Financial reiterated a “buy” rating and set a $82.00 price objective (up previously from $80.00) on shares of Lantheus in a research note on Monday, February 26th. B. Riley raised their price objective on shares of Lantheus from $95.00 to $99.00 and gave the company a “buy” rating in a research note on Thursday. Finally, JMP Securities reiterated a “market outperform” rating and set a $100.00 price objective on shares of Lantheus in a research note on Friday, February 23rd. One analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat, Lantheus currently has an average rating of “Moderate Buy” and an average price target of $104.71.

Lantheus Stock Performance

LNTH opened at $63.81 on Friday. The business’s 50 day moving average is $60.81 and its 200-day moving average is $62.88. The stock has a market cap of $4.37 billion, a PE ratio of 13.75 and a beta of 0.53. The company has a current ratio of 5.80, a quick ratio of 5.45 and a debt-to-equity ratio of 0.69. Lantheus has a twelve month low of $50.20 and a twelve month high of $100.85.

Insiders Place Their Bets

In other Lantheus news, major shareholder Lantheus Alpha Therapy, Llc purchased 60,431,039 shares of the firm’s stock in a transaction on Wednesday, March 6th. The shares were purchased at an average price of $0.95 per share, for a total transaction of $57,409,487.05. Following the completion of the transaction, the insider now owns 116,773,394 shares in the company, valued at approximately $110,934,724.30. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Lantheus news, Director Mary Anne Heino sold 93,863 shares of Lantheus stock in a transaction that occurred on Monday, March 4th. The shares were sold at an average price of $65.31, for a total transaction of $6,130,192.53. Following the transaction, the director now directly owns 251,643 shares in the company, valued at approximately $16,434,804.33. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, major shareholder Lantheus Alpha Therapy, Llc acquired 60,431,039 shares of the stock in a transaction on Wednesday, March 6th. The shares were purchased at an average price of $0.95 per share, for a total transaction of $57,409,487.05. Following the completion of the transaction, the insider now owns 116,773,394 shares in the company, valued at approximately $110,934,724.30. The disclosure for this purchase can be found here. Over the last 90 days, insiders have sold 94,545 shares of company stock worth $6,169,936. 1.50% of the stock is owned by insiders.

Hedge Funds Weigh In On Lantheus

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Macquarie Group Ltd. grew its position in Lantheus by 21.7% during the 1st quarter. Macquarie Group Ltd. now owns 605 shares of the medical equipment provider’s stock worth $50,000 after purchasing an additional 108 shares in the last quarter. Parkside Financial Bank & Trust grew its position in Lantheus by 36.6% during the 3rd quarter. Parkside Financial Bank & Trust now owns 582 shares of the medical equipment provider’s stock worth $40,000 after purchasing an additional 156 shares in the last quarter. RFG Advisory LLC boosted its stake in shares of Lantheus by 4.4% during the 3rd quarter. RFG Advisory LLC now owns 3,940 shares of the medical equipment provider’s stock valued at $274,000 after buying an additional 167 shares during the period. Prosperity Financial Group Inc. boosted its stake in shares of Lantheus by 6.2% during the 3rd quarter. Prosperity Financial Group Inc. now owns 2,967 shares of the medical equipment provider’s stock valued at $206,000 after buying an additional 173 shares during the period. Finally, Vanguard Personalized Indexing Management LLC boosted its stake in shares of Lantheus by 3.1% during the 3rd quarter. Vanguard Personalized Indexing Management LLC now owns 6,217 shares of the medical equipment provider’s stock valued at $432,000 after buying an additional 188 shares during the period. 99.06% of the stock is currently owned by hedge funds and other institutional investors.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.